ArticleExperimental hematology & oncology2026

Combination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer.

M Chiappa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.